Participant flow

UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide · Source last updated 2017-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Velcade, thalidomide, and dexamethasone + Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide \& Melphalan

   id

   FG000

   title

   VTD + DPACE/Melphalan

2. description

   Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide \& Melphalan

   id

   FG001

   title

   DPACE/Melphalan

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         10

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         10

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         10

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Participants are myeloma patients who have already received one or more treatment regimens and are seen at our facility

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice